Exelixis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,310

Employees1,310

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,310

Employees1,310

EXEL Key Statistics

Market cap

6.86B

Market cap6.86B

Price-Earnings ratio

35.39

Price-Earnings ratio35.39

Dividend yield

—

Dividend yield—

Average volume

1.98M

Average volume1.98M

High today

$23.68

High today$23.68

Low today

$23.02

Low today$23.02

Open price

$23.02

Open price$23.02

Volume

1.92M

Volume1.92M

52 Week high

$24.34

52 Week high$24.34

52 Week low

$18.08

52 Week low$18.08

EXEL News

Investor's Business Daily 18h

Exelixis Getting Closer To Key Technical Benchmark - Investor's Business Daily

Exelixis (EXEL) had its Relative Strength (RS) Rating upgraded from 69 to 75 Tuesday — a welcome improvement, but still short of the 80 or better score you look...

Simply Wall St 2d

Exelixis, Inc.'s Earnings Haven't Escaped The Attention Of Investors - Simply Wall St

Exelixis, Inc.'s ( ) price-to-earnings (or "P/E") ratio of 32x might make it look like a strong sell right now compared to the market in the United States, wher...

Simply Wall St 6d

Institutional investors in Exelixis, Inc. lost 3.8% last week but have reaped the benefits of longer-term growth

Key Insights Significantly high institutional ownership implies Exelixis' stock price is sensitive to their trading actions 51% of the business is held by the...

Analyst ratings

68%

of 22 ratings

Buy

68.2%

Hold

27.3%

Sell

4.5%